{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T11:27:00Z","timestamp":1792582020922,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T00:00:00Z","timestamp":1574121600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T00:00:00Z","timestamp":1574121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004350","name":"Studienstiftung des Deutschen Volkes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004350","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013373","name":"NIHR Oxford Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s40273-019-00856-8","type":"journal-article","created":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T03:01:30Z","timestamp":1574132490000},"page":"143-158","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A Review of Health Economic Studies Comparing Traditional and Massively Parallel Sequencing Diagnostic Pathways for Suspected Genetic Disorders"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2190-1513","authenticated-orcid":false,"given":"Patrick","family":"Fahr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2528-0638","authenticated-orcid":false,"given":"James","family":"Buchanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2361-3040","authenticated-orcid":false,"given":"Sarah","family":"Wordsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,19]]},"reference":[{"key":"856_CR1","unstructured":"National Institute of Health. What are genetic disorders? National Human Genome Research Institute. 2015. https:\/\/www.genome.gov\/19016930\/faq-about-genetic-disorders\/. Accessed 23 Jan 2019."},{"key":"856_CR2","unstructured":"Genetic Disorders UK. About genetic disorders. 2019. https:\/\/www.geneticdisordersuk.org\/aboutgeneticdisorders. Accessed 23 Jan 2019."},{"issue":"12","key":"856_CR3","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/gim.2018.39","volume":"20","author":"LJ Ewans","year":"2018","unstructured":"Ewans LJ, Schofield D, Shrestha R, Zhu Y, Gayevskiy V, Ying K, et al. Whole-exome sequencing reanalysis at 12\u00a0months boosts diagnosis and is cost-effective when applied early in Mendelian disorders. Genet Med. 2018;20(12):1564\u201374.","journal-title":"Genet Med."},{"issue":"9","key":"856_CR4","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/gim.2017.1","volume":"19","author":"L Vissers","year":"2017","unstructured":"Vissers L, van Nimwegen KJM, Schieving JH, Kamsteeg EJ, Kleefstra T, Yntema HG, et al. A clinical utility study of exome sequencing versus conventional genetic testing in pediatric neurology. Genet Med. 2017;19(9):1055\u201363.","journal-title":"Genet Med."},{"key":"856_CR5","doi-asserted-by":"publisher","unstructured":"Glossary of genomics terms. JAMA. 2013;309(14):1533\u20135. https:\/\/doi.org\/10.1001\/jama.2013.2950","DOI":"10.1001\/jama.2013.2950"},{"issue":"12","key":"856_CR6","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/gim.2014.58","volume":"16","author":"A Iglesias","year":"2014","unstructured":"Iglesias A, Anyane-Yeboa K, Wynn J, Wilson A, Cho MT, Guzman E, et al. The usefulness of whole-exome sequencing in routine clinical practice. Genet Med. 2014;16(12):922.","journal-title":"Genet Med"},{"issue":"2","key":"856_CR7","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/mgg3.355","volume":"6","author":"EE Palmer","year":"2018","unstructured":"Palmer EE, Schofield D, Shrestha R, Kandula T, Macintosh R, Lawson JA, et al. Integrating exome sequencing into a diagnostic pathway for epileptic encephalopathy: evidence of clinical utility and cost effectiveness. Mol Genet Genom Med. 2018;6(2):186\u201399.","journal-title":"Mol Genet Genom Med."},{"issue":"6","key":"856_CR8","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/gim.2015.41","volume":"17","author":"ACMG Board of Directors","year":"2015","unstructured":"ACMG Board of Directors. Clinical utility of genetic and genomic services: a position statement of the American College of Medical Genetics and Genomics. Genet Med. 2015;17(6):505.","journal-title":"Genet Med."},{"issue":"2","key":"856_CR9","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/ajmg.a.30571","volume":"133","author":"W Lenhard","year":"2005","unstructured":"Lenhard W, Breitenbach E, Ebert H, Schindelhauer-Deutscher H-J, Henn W. Psychological benefit of diagnostic certainty for mothers of children with disabilities: lessons from Down syndrome. Am J Med Genet Part A. 2005;133(2):170\u20135.","journal-title":"Am J Med Genet Part A."},{"issue":"14","key":"856_CR10","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMra1711801","volume":"379","author":"DR Adams","year":"2018","unstructured":"Adams DR, Eng CM. Next-generation sequencing to diagnose suspected genetic disorders. N Engl J Med. 2018;379(14):1353\u201362.","journal-title":"N Engl J Med."},{"issue":"1","key":"856_CR11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13023-016-0462-7","volume":"11","author":"G Baynam","year":"2016","unstructured":"Baynam G, Pachter N, McKenzie F, Townshend S, Slee J, Kiraly-Borri C, et al. The rare and undiagnosed diseases diagnostic service\u2014application of massively parallel sequencing in a state-wide clinical service. Orphanet J Rare Dis. 2016;11(1):77.","journal-title":"Orphanet J Rare Dis."},{"issue":"7","key":"856_CR12","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/ng.3304","volume":"47","author":"JC Taylor","year":"2015","unstructured":"Taylor JC, Martin HC, Lise S, Broxholme J, Cazier J-B, Rimmer A, et al. Factors influencing success of clinical genome sequencing across a broad spectrum of disorders. Nat Genet. 2015;47(7):717.","journal-title":"Nat Genet."},{"issue":"5","key":"856_CR13","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaneurol.2014.405","volume":"71","author":"J Wang","year":"2014","unstructured":"Wang J, Gotway G, Pascual JM, Park JY. Diagnostic yield of clinical next-generation sequencing panels for epilepsy. JAMA Neurol. 2014;71(5):650\u20131.","journal-title":"JAMA Neurol."},{"issue":"18","key":"856_CR14","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1001\/jama.2014.14604","volume":"312","author":"H Lee","year":"2014","unstructured":"Lee H, Deignan JL, Dorrani N, Strom SP, Kantarci S, Quintero-Rivera F, et al. Clinical exome sequencing for genetic identification of rare Mendelian disorders. JAMA. 2014;312(18):1880\u20137.","journal-title":"JAMA."},{"key":"856_CR15","unstructured":"NHS England. NHS genomic medicine service. 2018. https:\/\/www.england.nhs.uk\/genomics\/nhs-genomic-med-service\/. Accessed 24 Jan 2019."},{"issue":"9","key":"856_CR16","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/s41431-018-0175-6","volume":"26","author":"K Alam","year":"2018","unstructured":"Alam K, Schofield D. Economic evaluation of genomic sequencing in the paediatric population: a critical review. Eur J Hum Genet. 2018;26(9):1241\u20137.","journal-title":"Eur J Hum Genet."},{"issue":"10","key":"856_CR17","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/gim.2017.247","volume":"20","author":"K Schwarze","year":"2018","unstructured":"Schwarze K, Buchanan J, Taylor JC, Wordsworth S. Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature. Genet Med. 2018;20(10):1122\u201330.","journal-title":"Genet Med."},{"key":"856_CR18","volume-title":"The main methodological issues in costing health care services: a literature review","author":"Z Mogyorosy","year":"2005","unstructured":"Mogyorosy Z, Smith P. The main methodological issues in costing health care services: a literature review. York: Center for Health Economics; 2005."},{"issue":"7249","key":"856_CR19","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1136\/bmj.320.7249.1597","volume":"320","author":"J Raftery","year":"2000","unstructured":"Raftery J. Costing in economic evaluation. BMJ. 2000;320(7249):1597.","journal-title":"BMJ."},{"issue":"4","key":"856_CR20","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1524-4733.2008.00489.x","volume":"12","author":"M Drummond","year":"2009","unstructured":"Drummond M, Barbieri M, Cook J, Glick HA, Lis J, Malik F, et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value Health. 2009;12(4):409\u201318.","journal-title":"Value Health."},{"key":"856_CR21","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2015","unstructured":"Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2015."},{"issue":"7524","key":"856_CR22","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1136\/bmj.38636.593461.68","volume":"331","author":"T Greenhalgh","year":"2005","unstructured":"Greenhalgh T, Peacock R. Effectiveness and efficiency of search methods in systematic reviews of complex evidence: audit of primary sources. BMJ. 2005;331(7524):1064\u20135.","journal-title":"BMJ."},{"issue":"1","key":"856_CR23","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1332\/174426410X482999","volume":"6","author":"I Shemilt","year":"2010","unstructured":"Shemilt I, Thomas J, Morciano M. A web-based tool for adjusting costs to a specific target currency and price year. Evid Policy J Res Debate Pract. 2010;6(1):51\u20139.","journal-title":"Evid Policy J Res Debate Pract."},{"issue":"2","key":"856_CR24","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","volume":"16","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS)\u2014explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013;16(2):231\u201350.","journal-title":"Value Health"},{"issue":"6","key":"856_CR25","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s40273-015-0261-3","volume":"33","author":"J Buchanan","year":"2015","unstructured":"Buchanan J, Wordsworth S. Welfarism versus extra-welfarism: can the choice of economic evaluation approach impact on the adoption decisions recommended by economic evaluation studies? PharmacoEconomics. 2015;33(6):571\u20139.","journal-title":"PharmacoEconomics."},{"key":"856_CR26","unstructured":"The World Bank. World Bank Country and Lending Group. 2019. https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups. Accessed 29 Jan 2019."},{"issue":"3","key":"856_CR27","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jmoldx.2015.11.010","volume":"18","author":"LM Sabatini","year":"2016","unstructured":"Sabatini LM, Mathews C, Ptak D, Doshi S, Tynan K, Hegde MR, et al. Genomic sequencing procedure microcosting analysis and health economic cost-impact analysis: a report of the association for molecular pathology. J Mol Diagn. 2016;18(3):319\u201328.","journal-title":"J Mol Diagn."},{"issue":"11","key":"856_CR28","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/gim.2017.47","volume":"19","author":"K Tsiplova","year":"2017","unstructured":"Tsiplova K, Zur RM, Marshall CR, Stavropoulos DJ, Pereira SL, Merico D, et al. A microcosting and cost-consequence analysis of clinical genomic testing strategies in autism spectrum disorder. Genet Med. 2017;19(11):1268\u201375.","journal-title":"Genet Med."},{"issue":"7","key":"856_CR29","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1177\/0883073815627880","volume":"31","author":"D Nolan","year":"2016","unstructured":"Nolan D, Carlson M. Whole exome sequencing in pediatric neurology patients: clinical implications and estimated cost analysis. J Child Neurol. 2016;31(7):887\u201394.","journal-title":"J Child Neurol."},{"key":"856_CR30","doi-asserted-by":"crossref","first-page":"6421039","DOI":"10.1155\/2016\/6421039","volume":"2016","author":"C Joshi","year":"2016","unstructured":"Joshi C, Kolbe DL, Mansilla MA, Mason SO, Smith RJ, Campbell CA. Reducing the cost of the diagnostic odyssey in early onset epileptic encephalopathies. Biomed Res Int. 2016;2016:6421039.","journal-title":"Biomed Res Int."},{"issue":"2","key":"856_CR31","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/gim.2013.99","volume":"16","author":"V Shashi","year":"2014","unstructured":"Shashi V, McConkie-Rosell A, Rosell B, Schoch K, Vellore K, McDonald M, et al. The utility of the traditional medical genetics diagnostic evaluation in the context of next-generation sequencing for undiagnosed genetic disorders. Genet Med. 2014;16(2):176\u201382.","journal-title":"Genet Med."},{"issue":"265","key":"856_CR32","doi-asserted-by":"crossref","first-page":"265ra168","DOI":"10.1126\/scitranslmed.3010076","volume":"6","author":"SE Soden","year":"2014","unstructured":"Soden SE, Saunders CJ, Willig LK, Farrow EG, Smith LD, Petrikin JE, et al. Effectiveness of exome and genome sequencing guided by acuity of illness for diagnosis of neurodevelopmental disorders. Sci Transl Med. 2014;6(265):265ra168.","journal-title":"Sci Transl Med"},{"issue":"1","key":"856_CR33","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41525-017-0006-7","volume":"2","author":"D Schofield","year":"2017","unstructured":"Schofield D, Alam K, Douglas L, Shrestha R, MacArthur DG, Davis M, et al. Cost-effectiveness of massively parallel sequencing for diagnosis of paediatric muscle diseases. NPJ Genom Med. 2017;2(1):4.","journal-title":"NPJ Genom Med"},{"issue":"5","key":"856_CR34","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/acn3.409","volume":"4","author":"M Walsh","year":"2017","unstructured":"Walsh M, Bell KM, Chong B, Creed E, Brett GR, Pope K, et al. Diagnostic and cost utility of whole exome sequencing in peripheral neuropathy. Ann Clin Transl Neurol. 2017;4(5):318\u201325.","journal-title":"Ann Clin Transl Neurol."},{"issue":"6","key":"856_CR35","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/epi.14087","volume":"59","author":"KB Howell","year":"2018","unstructured":"Howell KB, Eggers S, Dalziel K, Riseley J, Mandelstam S, Myers CT, et al. A population-based cost-effectiveness study of early genetic testing in severe epilepsies of infancy. Epilepsia. 2018;59(6):1177\u201387.","journal-title":"Epilepsia."},{"key":"856_CR36","volume-title":"Whole exome sequencing in clinical genetics\u2014a health economic evaluation","author":"GS Sagoo","year":"2017","unstructured":"Sagoo GS, Norbury G, Mohammed S, Kroese M. Whole exome sequencing in clinical genetics\u2014a health economic evaluation. Cambridge: PHG Foundation; 2017."},{"key":"856_CR37","first-page":"139329","volume":"2017","author":"M Demos","year":"2017","unstructured":"Demos M, Guella I, McKenzie MB, Buerki SE, Evans DM, Toyota EB, et al. Diagnostic yield and treatment impact of targeted exome sequencing in early-onset epilepsy. bioRxiv. 2017;2017:139329.","journal-title":"bioRxiv."},{"issue":"8","key":"856_CR38","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/gim.2016.221","volume":"19","author":"Z Stark","year":"2017","unstructured":"Stark Z, Schofield D, Alam K, Wilson W, Mupfeki N, Macciocca I, et al. Prospective comparison of the cost-effectiveness of clinical whole-exome sequencing with that of usual care overwhelmingly supports early use and reimbursement. Genet Med. 2017;19(8):867\u201374.","journal-title":"Genet Med"},{"issue":"9","key":"856_CR39","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1001\/jamapediatrics.2017.1755","volume":"171","author":"TY Tan","year":"2017","unstructured":"Tan TY, Dillon OJ, Stark Z, Schofield D, Alam K, Shrestha R, et al. Diagnostic impact and cost-effectiveness of whole-exome sequencing for ambulant children with suspected monogenic conditions. JAMA Pediatr. 2017;171(9):855\u201362.","journal-title":"JAMA Pediatr."},{"issue":"2","key":"856_CR40","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ejpn.2014.12.014","volume":"19","author":"KJ van Nimwegen","year":"2015","unstructured":"van Nimwegen KJ, Schieving JH, Willemsen MA, Veltman JA, van der Burg S, van der Wilt GJ, et al. The diagnostic pathway in complex paediatric neurology: a cost analysis. Eur J Paediatr Neurol. 2015;19(2):233\u20139.","journal-title":"Eur J Paediatr Neurol."},{"issue":"11","key":"856_CR41","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1038\/s41431-018-0203-6","volume":"26","author":"T Vrijenhoek","year":"2018","unstructured":"Vrijenhoek T, Middelburg EM, Monroe GR, van Gassen KL, Geenen JW, H\u00f6vels AM, et al. Whole-exome sequencing in intellectual disability; cost before and after a diagnosis. Eur J Hum Genet. 2018;26(11):1566.","journal-title":"Eur J Hum Genet."},{"key":"856_CR42","volume-title":"Cost-effectiveness of diagnostic whole exome sequencing in complex paediatric neurology","author":"GJ van der Wilt","year":"2017","unstructured":"van der Wilt GJ, van Nimwegen KJM, Vissers LELM, Schieving JH, Willemsen MAAP, Veltman JA, et al. Cost-effectiveness of diagnostic whole exome sequencing in complex paediatric neurology. Nijmegen: Radboud University Nijmegen; 2017."},{"issue":"9","key":"856_CR43","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/gim.2015.200","volume":"18","author":"GR Monroe","year":"2016","unstructured":"Monroe GR, Frederix GW, Savelberg SM, de Vries TI, Duran KJ, van der Smagt JJ, et al. Effectiveness of whole-exome sequencing and costs of the traditional diagnostic trajectory in children with intellectual disability. Genet Med. 2016;18(9):949\u201356.","journal-title":"Genet Med."},{"issue":"2","key":"856_CR44","doi-asserted-by":"crossref","first-page":"e0191228","DOI":"10.1371\/journal.pone.0191228","volume":"13","author":"M Cordoba","year":"2018","unstructured":"Cordoba M, Rodriguez-Quiroga SA, Vega PA, Salinas V, Perez-Maturo J, Amartino H, et al. Whole exome sequencing in neurogenetic odysseys: an effective, cost- and time-saving diagnostic approach. PLoS One. 2018;13(2):e0191228.","journal-title":"PLoS One."},{"issue":"11","key":"856_CR45","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1002\/ajmg.a.37215","volume":"167A","author":"J Richards","year":"2015","unstructured":"Richards J, Korgenski EK, Taft RJ, Vanderver A, Bonkowsky JL. Targeted leukodystrophy diagnosis based on charges and yields for testing. Am J Med Genet A. 2015;167A(11):2541\u20133.","journal-title":"Am J Med Genet A."},{"issue":"1","key":"856_CR46","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/humu.22451","volume":"35","author":"SL Sawyer","year":"2014","unstructured":"Sawyer SL, Schwartzentruber J, Beaulieu CL, Dyment D, Smith A, Chardon JW, et al. Exome sequencing as a diagnostic tool for pediatric-onset ataxia. Hum Mutat. 2014;35(1):45\u20139.","journal-title":"Hum Mutat."},{"issue":"3","key":"856_CR47","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.mayocp.2015.12.018","volume":"91","author":"KN Lazaridis","year":"2016","unstructured":"Lazaridis KN, Schahl KA, Cousin MA, Babovic-Vuksanovic D, Riegert-Johnson DL, Gavrilova RH, et al. Outcome of whole exome sequencing for diagnostic odyssey cases of an individualized medicine clinic: the Mayo Clinic experience. Mayo Clin Proc. 2016;91(3):297\u2013307.","journal-title":"Mayo Clin Proc."},{"issue":"9","key":"856_CR48","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/gim.2017.226","volume":"20","author":"N Dragojlovic","year":"2018","unstructured":"Dragojlovic N, Elliott AM, Adam S, van Karnebeek C, Lehman A, Mwenifumbo JC, et al. The cost and diagnostic yield of exome sequencing for children with suspected genetic disorders: a benchmarking study. Genet Med. 2018;20(9):1013\u201321.","journal-title":"Genet Med."},{"key":"856_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-019-0635-6","author":"N Dragojlovic","year":"2019","unstructured":"Dragojlovic N, van Karnebeek CD, Ghani A, Genereaux D, Kim E, Birch P, et al. The cost trajectory of the diagnostic care pathway for children with suspected genetic disorders. Genet Med. 2019. https:\/\/doi.org\/10.1038\/s41436-019-0635-6(Epub 29 Aug 2019).","journal-title":"Genet Med"},{"issue":"7","key":"856_CR50","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/gim.2015.148","volume":"18","author":"K Retterer","year":"2016","unstructured":"Retterer K, Juusola J, Cho MT, Vitazka P, Millan F, Gibellini F, et al. Clinical application of whole-exome sequencing across clinical indications. Genet Med. 2016;18(7):696.","journal-title":"Genet Med."},{"key":"856_CR51","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41436-018-0006-8","volume":"21","author":"Z Stark","year":"2019","unstructured":"Stark Z, Schofield D, Martyn M, Rynehart L, Shrestha R, Alam K, et al. Does genomic sequencing early in the diagnostic trajectory make a difference? A follow-up study of clinical outcomes and cost-effectiveness. Genet Med. 2019;21:173\u201380.","journal-title":"Genet Med."},{"key":"856_CR52","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1038\/s41436-019-0534-x","volume":"21","author":"D Schofield","year":"2019","unstructured":"Schofield D, Rynehart L, Shresthra R, White SM, Stark Z. Long-term economic impacts of exome sequencing for suspected monogenic disorders: diagnosis, management, and reproductive outcomes. Genet Med. 2019;21:2586\u201393.","journal-title":"Genet Med."},{"issue":"6","key":"856_CR53","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1399-0004.2009.01193.x","volume":"75","author":"DA Regier","year":"2009","unstructured":"Regier DA, Friedman JM, Makela N, Ryan M, Marra CA. Valuing the benefit of diagnostic testing for genetic causes of idiopathic developmental disability: willingness to pay from families of affected children. Clin Genet. 2009;75(6):514\u201321.","journal-title":"Clin Genet."},{"issue":"8","key":"856_CR54","doi-asserted-by":"crossref","first-page":"596","DOI":"10.3111\/13696998.2015.1033423","volume":"18","author":"J Frappier","year":"2015","unstructured":"Frappier J, Tremblay G, Charny M, Cloutier LM. Costing bias in economic evaluations. J Med Econ. 2015;18(8):596\u20139.","journal-title":"J Med Econ."},{"issue":"1","key":"856_CR55","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/2046-4053-3-47","volume":"3","author":"X Xu","year":"2014","unstructured":"Xu X, Nardini HKG, Ruger JP. Micro-costing studies in the health and medical literature: protocol for a systematic review. Syst Rev. 2014;3(1):47.","journal-title":"Syst Rev."},{"issue":"1","key":"856_CR56","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1586\/14737167.2.1.29","volume":"2","author":"A Heerey","year":"2002","unstructured":"Heerey A, McGowan B, Ryan M, Barry M. Microcosting versus DRGs in the provision of cost estimates for use in pharmacoeconomic evaluation. Expert Rev Pharmacoecon Outcomes Res. 2002;2(1):29\u201333.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-019-00856-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-019-00856-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-019-00856-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T04:49:42Z","timestamp":1605674982000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-019-00856-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,19]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["856"],"URL":"https:\/\/doi.org\/10.1007\/s40273-019-00856-8","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,19]]},"assertion":[{"value":"19 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Patrick Fahr declares no conflicts of interest. James Buchanan and Sarah Wordsworth are co-applicants of a project funded through Genome British Columbia\u2019s GeneSolve program and Illumina, and have received travel funding from Illumina to attend conferences.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}